H. Lundbeck A/S
HLUN-A.CO
NASDAQ Copenhagen37.05
DKK
+0.10
- -
H. Lundbeck A/S
HLUN-A.CO
(NASDAQ Copenhagen)
Recent
price
37.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- H. Lundbeck A/S is a Danish international pharmaceutical company specializing exclusively in the research, development, manufacturing, and commercialization of pharmaceuticals for the treatment of psychiatric and neurological disorders. The company’s core products include proprietary pharmaceuticals addressing brain diseases such as depression, anxiety, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, and other central nervous system disorders. It offers a wide portfolio with key strategic brands including Vyepti for migraine, Trintellix for depression, and Rexulti for schizophrenia and bipolar disorder, alongside several investigational drugs for neuro-rare and neuro-specialty diseases. Lundbeck markets its products globally, with registration in over 100 countries and operations spanning Europe, North America, and international markets. The company is headquartered in Copenhagen, Denmark, was founded in 1915, and maintains manufacturing facilities in Denmark, France, and Italy as well as research centers in Denmark and the United States. In 2024 and 2025, Lundbeck has pursued significant strategic developments enhancing its market presence and pipeline strength. In October 2024, Lundbeck agreed to acquire Longboard Pharmaceuticals, a U.S.-based epilepsy drug manufacturer, in a $2.6 billion deal, representing its largest acquisition to date. This acquisition strengthens Lundbeck’s neurology portfolio, especially in developing treatments for epilepsy and related central nervous system conditions. Additionally, in September 2025, Lundbeck initiated a major commercial transformation, transitioning its operations in 27 European and international markets to a partnership model with entities such as Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. This strategic shift aims to sharpen commercial focus, reduce operational complexity, and reallocate capital to high-growth neuro-rare and neuro-specialty disease franchises. In 2025, Lundbeck also showcased progress with investigational molecules such as amlenetug for multiple system atrophy, emphasizing advanced clinical development programs leveraging innovative methodologies. Lundbeck operates primarily within the pharmaceuticals and biotech industry, targeting healthcare providers, hospitals, and specialty clinics treating brain disorders. The company has approximately 5,600 employees and is publicly listed on the Copenhagen Stock Exchange. Its strategic priorities revolve around expanding its leadership in brain diseases through a focused innovator strategy, driven by robust research and development capabilities and a growing late-stage pipeline of neuro-rare and neuro-specialty disease treatments. The recent changes reflect Lundbeck’s commitment to strengthening its global footprint, optimizing commercial execution, and advancing novel therapies for enduring neurological and psychiatric conditions.